Clinical Predictors of Durable Clinical Benefit of Pembrolizumab Therapy in Veterans With Metastatic Non–Small Cell Lung Cancer

International Journal of Radiation Oncology Biology Physics - Netherlands
doi 10.1016/j.ijrobp.2017.01.141
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P1.01-12 SWItch Maintenance PEmbrolizumab in Patients With Metastatic Non Small Cell Lung Cancer (SWIPE)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Pcn4 - Effectiveness and Safety of Pembrolizumab in Advanced or Metastatic Non-Small Cell Lung Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Metastatic Non-Small Cell Lung Cancer in Brazil: Treatment Heterogeneity in Routine Clinical Practice

Clinics
Medicine
2007English

Taxotere: Clinical Trials in Non‐Small Cell Lung Cancer

Oncologist
Cancer ResearchMedicineOncology
1998English

Individualized Therapy in Non-Small-Cell Lung Cancer: Future Versus Current Clinical Practice

Oncogene
Cancer ResearchGeneticsMolecular Biology
2009English

P1.01-24 Clinical Efficacy of Immunotherapy in Metastatic Non-Small Cell Lung Cancer Patients Treated With Prior Radiotherapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Clinical Outcome of Treatment of Metastatic Non-Small Cell Lung Cancer in Patients Harboring Uncommon EGFR Mutation

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Potential Clinical Application of lncRNAs in Non-Small Cell Lung Cancer

OncoTargets and Therapy
OncologyPharmacology
2018English

Nivolumab in Metastatic Non–Small Cell Lung Cancer

Journal of the Advanced Practitioner in Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy